Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will participate as Company Spotlight presenter at the 4th Annual Dermatology Innovation Forum. The company presentation will be on Thursday, February 15, 2018 at 2:40 pm PT at the Manchester Grand Hyatt in San Diego, CA.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology and dermatology biopharmaceutical company developing first-in-class drugs. Its breakthrough immuno-metabolic platform technology targets hexokinase 2 (HK2), a metabolic master regulator of proliferation, affecting both cancer and immune cells. Vidac’s drugs modulate HK2-mitochondria binding to trigger selective tumor apoptosis (without affecting the surrounding healthy tissue), reduce metabolite immunosuppression in tumor microenvironment, and stimulate anti-tumor immune response. HK2 is over-expressed in a broad range of tumors, especially with tumor-suppression mutations. Vidac’s lead drug, VDA-1102 (ointment), completed Phase 2 POC trial in Actinic Keratosis, an early form of cutaneous SCC, demonstrating safety, tolerability and efficacy. Vidac is also developing systemic (oral) treatments for solid tumors and hematological malignancies, as monotherapies and in combinations. For more information please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
